NOBILIS ND C2

Authorised

- Newcastle disease virus, Live

Product identification

Medicine name:
Nobilis ND C2 liofilizado para suspensão oculonasal para galinhas
NOBILIS ND C2

Active substance:
Newcastle disease virus, Live

Target species:
Chicken

Route of administration:
Oculonasal use
Nebulisation use

Product details

Active substance and strength:
Newcastle disease virus, Live
5.70 unit(s) / 1.00 Dose

Pharmaceutical form:
Lyophilisate for suspension

Withdrawal period by route of administration:
Oculonasal use:

- **Chicken**
  - All relevant tissues. 0 day

Nebulisation use:

- **Chicken**
  - All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD06

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Portugal

Package description:
Cardboard box with 1 vial of 500 doses.
Cardboard box with 1 vial of 5000 doses.
PET plastic boxes with 12 cups of 5000 doses
PET plastic boxes with 12 cups of 2500 doses
PET plastic boxes with 12 cups of 10000 doses
PET plastic boxes with 12 cups of 1000 doses
Cardboard box with 1 vial of 25000 doses.
Cardboard box with 1 vial of 2500 doses.
Cardboard box with 1 vial of 10000 doses.
Cardboard box with 1 vial of 1000 doses.
Cardboard box with 10 vials of 1000 doses.
Cardboard box with 10 vials of 10000 doses.
Cardboard box with vials of 2500 doses.
Cardboard box with 10 vials of 25000 doses.
Cardboard box with 10 vials of 5000 doses.
Cardboard box with 10 vials of 500 doses.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
MSD Animal Health Lda.

Marketing authorisation date:
13/05/2005

Manufacturing sites for batch release:
INTERVET INTERNATIONAL B.V.

Responsible authority:
DGAV

Authorisation number:
R746/05 DGV

Date of authorisation status change:
13/05/2005

Reference member state:
Netherlands

Procedure number:
NL/V/0113/001

Concerned member states:
Belgium Cyprus Czechia Denmark Estonia Germany Greece Ireland Italy Latvia Lithuania Luxembourg Poland Portugal Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

---